Our results were in agreement with recent findings describing the efficacy of BET inhibitors in a KRAS-driven NSCLC mouse model.11 Using GSEA, we confirmed that the MYC transcriptional program was altered in JQ1-treated DV90 cells. Here, KRAS is linked to non-small cell lung carcinoma.